Stay updated with breaking news from Lung cancer res. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
For EU Trade and Medical Media Only. Not to Be Distributed to UK and Benelux Based Media Conditional Marketing Authorisation is based on results from the Phase 1 CHRYSALIS study evaluating amivantamab ....
If approved by the European Commission, amivantamab will be the first treatment in the European Union specifically targeting EGFR exon 20 insertion mutations for advanced non-small cell lung cancer ....
Findings to be presented at the ASCO Annual Meeting show preliminary efficacy in patients with EGFR-mutated NSCLC and Janssen's commitment to address the need for new targeted therapies for this patient ....
Janssen: New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations FOR EU TRADE AND MEDICAL MEDIA ONLY Not for distribution in the UK and Benelux The Janssen Pharmaceutical Companies of Johnson Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy. 1 These data were presented for the first time in an oral presentation at the International Association for the Study of Lung Cancer s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore. The key findings showed robust activity and durable responses with a tolerable and manageable safety profile (Abstract #3031) in patien ....